FDA — authorised 12 February 2021
- Application: NDA214200
- Marketing authorisation holder: PHARMACOSMOS
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 TRILACICLIB in United States
FDA authorised TRILACICLIB on 12 February 2021
Marketing authorisation
TRILACICLIB in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is TRILACICLIB approved in United States?
Yes. FDA authorised it on 12 February 2021.
Who is the marketing authorisation holder for TRILACICLIB in United States?
PHARMACOSMOS holds the US marketing authorisation.